Molecular structure of one of Alzheimer's stickier culprits

"Roughly ten percent of Alzheimer's disease cases are the result of identified mutations," says Liliya Vugmeyster, PhD, associate professor in the department of chemistry, College of Liberal Arts & Sciences, at CU Denver. "But 90 percent of Alzheimer's cases are not explained by these mutations, which is why we need to understand the molecular base of the disease."

Alzheimer's disease begins decades before the onset of symptoms. It starts the day microscopic, toxic protein fragments called beta amyloids (A?) glom onto each other. Those clumps form chains called fibrils, which band together to become a sticky, pleated sheet that builds on brain cells like plaque. As it accumulates, the plaque disrupts cell membranes and the communication between brain cells, causing them to die. Until now, understanding just the molecular makeup of the proteins -- and the more aggressive subtypes that cause a rapid acceleration of the disease -- has plagued researchers.

In this collaborative study with Wei Qiang, assistant professor of biophysical chemistry at Binghamton University, researchers targeted the structure and the dynamics of the aggressive, "seeding-prone" Ser-8-phosphorylated 40-residue A? (pS8-A?40) fibrils. They found that even when it existed in smaller amounts, pS8-A?40 acted as the alpha in structure polymorphism. It also had a higher level of cellular toxicity compared to other fibrils. In looking at the molecular structure, researchers found that the N-terminus, the creation point of the protein, played an important role in manipulating both the fibrils structures and the aggregation processes.

Vugmeyster, along with student Dan Fai Au, M.S., and Dmitry Ostrovsky, instructor in mathematical and statistical sciences, studied the flexibility of the fibrils. In previous research, Vugmeyster found that flexibility could be part of the control mechanism for plaque accumulation.

"Fibrils are very resilient to treatment that prevents aggregation," says Vugmeyster. "Whatever you do to them in the test tubes, they adjust, find a way to go into a toxic state and aggregate."

Vugmeyster says mapping the structure of pS8-A?40 is just the first piece of a larger puzzle. Qiang's group at Binghampton and her team plan do the same for several important protein modifications, focusing on the static structure, dynamics and stability of each. Eventually, she says, this information might one day lead to ideas how to come up with drugs that can break the vicious cycle of cell degeneration.